JP6901545B2 - Ｉｌ−４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法 - Google Patents

Ｉｌ−４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法 Download PDF

Info

Publication number
JP6901545B2
JP6901545B2 JP2019227843A JP2019227843A JP6901545B2 JP 6901545 B2 JP6901545 B2 JP 6901545B2 JP 2019227843 A JP2019227843 A JP 2019227843A JP 2019227843 A JP2019227843 A JP 2019227843A JP 6901545 B2 JP6901545 B2 JP 6901545B2
Authority
JP
Japan
Prior art keywords
dose
antibody
pharmaceutical composition
baseline
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019227843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020059749A (ja
Inventor
マリアス・アーデリアヌ
ニール・グレアム
ジェニファー・ディー・ハミルトン
ステファーヌ・シー・キルケッセリ
サディープ・クンドゥ
ジェフリー・ミーン
アレン・ラディン
ロス・イー・ロックリン
スティーヴン・ピー・ウェインスティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2018109925A external-priority patent/JP6637113B2/ja
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020059749A publication Critical patent/JP2020059749A/ja
Priority to JP2021099837A priority Critical patent/JP7256231B2/ja
Application granted granted Critical
Publication of JP6901545B2 publication Critical patent/JP6901545B2/ja
Priority to JP2023052545A priority patent/JP2023082091A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019227843A 2012-09-07 2019-12-18 Ｉｌ−４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法 Active JP6901545B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021099837A JP7256231B2 (ja) 2012-09-07 2021-06-16 Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法
JP2023052545A JP2023082091A (ja) 2012-09-07 2023-03-29 Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201261697972P 2012-09-07 2012-09-07
US61/697,972 2012-09-07
US201261738715P 2012-12-18 2012-12-18
US61/738,715 2012-12-18
US201361748588P 2013-01-03 2013-01-03
US61/748,588 2013-01-03
US201361764624P 2013-02-14 2013-02-14
US61/764,624 2013-02-14
US201361768229P 2013-02-22 2013-02-22
US61/768,229 2013-02-22
US201361770091P 2013-02-27 2013-02-27
US61/770,091 2013-02-27
US201361782420P 2013-03-14 2013-03-14
US61/782,420 2013-03-14
US201361816191P 2013-04-26 2013-04-26
US61/816,191 2013-04-26
FR1356759 2013-07-10
FR1356759 2013-07-10
JP2018109925A JP6637113B2 (ja) 2012-09-07 2018-06-08 Ｉｌ−４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018109925A Division JP6637113B2 (ja) 2012-09-07 2018-06-08 Ｉｌ−４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021099837A Division JP7256231B2 (ja) 2012-09-07 2021-06-16 Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法

Publications (2)

Publication Number Publication Date
JP2020059749A JP2020059749A (ja) 2020-04-16
JP6901545B2 true JP6901545B2 (ja) 2021-07-14

Family

ID=67734429

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019227843A Active JP6901545B2 (ja) 2012-09-07 2019-12-18 Ｉｌ−４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法
JP2021099837A Active JP7256231B2 (ja) 2012-09-07 2021-06-16 Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021099837A Active JP7256231B2 (ja) 2012-09-07 2021-06-16 Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法

Country Status (8)

Country Link
JP (2) JP6901545B2 (pt)
KR (1) KR102284244B1 (pt)
HK (1) HK1251896A1 (pt)
IL (2) IL266941A (pt)
MX (1) MX2019002801A (pt)
PT (1) PT2892927T (pt)
SG (1) SG10201913822PA (pt)
TW (1) TWI790457B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110746507B (zh) * 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor

Also Published As

Publication number Publication date
PT2892927T (pt) 2018-08-02
IL278968B (en) 2021-09-30
SG10201913822PA (en) 2020-03-30
MX2019002801A (es) 2019-07-15
TW202041536A (zh) 2020-11-16
JP2020059749A (ja) 2020-04-16
HK1251896A1 (zh) 2019-04-26
JP2021152042A (ja) 2021-09-30
KR102284244B1 (ko) 2021-08-03
TWI790457B (zh) 2023-01-21
KR20200069388A (ko) 2020-06-16
IL278968A (en) 2021-01-31
JP7256231B2 (ja) 2023-04-11
IL266941A (en) 2019-07-31

Similar Documents

Publication Publication Date Title
JP6637113B2 (ja) Ｉｌ−４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法
JP6901545B2 (ja) Ｉｌ−４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法
TW202412839A (zh) 藉由投與il-4r拮抗劑治療異位性皮膚炎的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20210112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210331

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210518

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210617

R150 Certificate of patent or registration of utility model

Ref document number: 6901545

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150